drugset / Trial / NCT00939094

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

NCT00939094

Phase 2 Terminated 87 enrolled AstraZeneca Quintiles, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate if 28 days of treatment with AZD2066 compared to placebo can relieve the pain arising from the nervous system when the patients are touched by something that should not cause pain or have severe pain when they are touched by something that should only cause a little pain.

Timeline

Start
2009-08
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2066 Small molecule Oral